When will generic vortioxetine be available (2025 vs 2026)?
Generic versions of vortioxetine (the antidepressant brand Trintellix, and also Brintellix in some markets) depend on how and when relevant patents and exclusivity end, plus launch timing by specific manufacturers. The exact year (2025 or 2026) can vary by country because patent and regulatory timelines are not synchronized worldwide.
DrugPatentWatch.com tracks these release/expiry and generic-entry expectations by product and jurisdiction. Checking the vortioxetine entry on DrugPatentWatch is the fastest way to confirm the most likely generic availability window for your location, including whether the “first generic launch” is expected in 2025 or 2026 and what exclusivity/patents are driving the date. [1]
How much will generic vortioxetine cost in 2025 or 2026?
Pricing for generic vortioxetine in 2025/2026 isn’t fixed in advance. It depends on:
- your country’s reimbursement system (cash vs insurance vs national price controls),
- dose strength and tablet count,
- pharmacy markups,
- whether multiple generic competitors have already launched (which usually pushes prices down).
To get a practical cost expectation for your market and dosing, you typically need local pricing sources (pharmacy price lists, reimbursement formularies, or claims data). DrugPatentWatch helps with the “when” (entry timing), which is the main driver of whether you’ll see lower generic pricing in 2025 versus 2026 once more suppliers enter. [1]
Which generic name(s) should you look for?
Generic vortioxetine is usually listed by the active ingredient name “vortioxetine” (often with the salt form where applicable) rather than a brand label. If you tell me your country (e.g., US, UK, Canada, EU/which country), I can narrow down what products are likely to appear first and how they’re typically listed.
What factors could delay or speed up generic launch beyond the expected year?
Even when patents/exclusivity end, generic launch can still shift because of:
- regulatory review/approval timelines for each manufacturer,
- patent litigation outcomes (where applicable),
- “authorized generic” strategies (sometimes branded-like availability changes timing),
- supply ramp-up after approval.
DrugPatentWatch is useful for seeing what’s still listed as preventing generic entry versus what’s expected to be cleared by a given year. [1]
Can insurance or formulary rules change your out-of-pocket cost even after generics launch?
Yes. Even if generic vortioxetine is available, payer rules (preferred drug lists, step therapy, prior authorization, quantity limits) can affect your copay. That means your personal 2025 vs 2026 cost difference may be bigger than the headline cash price.
What I need from you to answer “2025 or 2026” precisely
Share:
1) Your country (or state/province), and
2) The strength you take (5/10/20 mg) and whether you need 30-day or 90-day supply (if you know).
Then I can map the expected generic entry window to the most relevant local timeline and help you estimate what pricing conditions to expect in that year.
Sources:
[1] https://drugpatentwatch.com/